Sort   by:  
 Page size 
ProteomicsA Comprehensive Proteomics Study on Platelet Concentrates: Platelet Proteome, Storage Time and Mirasol Pathogen Reduction Technology
Platelet concentrates (PCs) represent a blood transfusion product with a major concern for safety as their storage temperature (20-24ºC) allows bacterial growth, and their maximum storage time period (less than a week) precludes complete microbiological testing. Pathogen inactivation technologies (P...
ORGANISM(S): Homo sapiens (Human) 
2018-03-23 | PXD008119 | Pride
Platelet function tests Storage time Platelet transfusion Pathogen inactivation technologies Blood safety Proteomics 
GenomicsGenome-Wide Association of Native and Post Aspirin Platelet Function Phenotypes

The goal of this study was to identify genetic variants in a genome-wide association study (GWAS) that are associated with previously obtained platelet function phenotypes measured in each individual under baseline conditions and following 2 weeks of low dose aspirin (ASA). During this study we p...

phs000375.v1.p1 | EGA
ProteomicsProteomic landscapes of inherited platelet disorders with different etiologies
Background: Inherited Platelet Disorders (IPDs) are a heterogeneous group of rare diseases that are caused by defects in early megakaryopoiesis, pro-platelet formation and/or mature platelet function. Although genomic sequencing is increasingly used to identify genetic variants underlying IPD, this ...
ORGANISM(S): Homo sapiens (Human) 
2023-01-31 | PXD027463 | Pride
Human Platelets Orbitrap fusion 
UnknownPlatelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s.
Not available
S-EPMC7019825 | biostudies-literature
UnknownClopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume.
Not available
S-EPMC8650403 | biostudies-literature
GenomicPharmacogenomics of Anti-Platelet Intervention (PAPI) Study

CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent, which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not r...

phs000391 | dbGaP
UnknownPlatelet function testing: Current practice among clinical centres in Northern Europe.
Not available
S-EPMC9540416 | biostudies-literature
GenomicsDetermining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent, which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not r...

phs000391.v1.p1 | EGA
UnknownMultiparameter platelet function analysis of bleeding patients with a prolonged platelet function analyser closure time.
Not available
S-EPMC9303561 | biostudies-literature
Proteomicsimmune thrombocytopenia in sitosterolemia is driven by lipid disorder and not proteomic aberrations
Sitosterolemia is a rare autosomal-recessive genetic disorder in which patients develop hypercholesterolemia, and abnormal hematologic and/or liver function tests. In this disease, dysfunction of either ABCG5 or ABCG8 results in intestinal hyperabsorption of all sterols, including cholesterol and mo...
ORGANISM(S): Homo sapiens (Human) 
2024-06-16 | PXD041248 | Pride
Sitosterolemia Platelet proteomics 
Sort   by:  
 Page size